Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors

Vaccine

Volumn 27, Issue 44, 2009, Pages 6148-6153

  Yu, Yunzhou ^a   Yu, Jiyu ^b   Li, Na ^a   Wang, Shuang ^a   Yu, Weiyuan ^a   Sun, Zhiwei ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Botulinum neurotoxin; Replicon vector; Vaccine

Indexed keywords

BACTERIAL VACCINE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; DNA REPLICON VACCINE PSCARSA BHC; DNA REPLICON VACCINE PSCARSAHC; DNA REPLICON VACCINE PSCARSBHC; DNA VACCINE; RECOMBINANT SEMLIKI FOREST VIRUS REPLICON PARTICLE AHC; RECOMBINANT SEMLIKI FOREST VIRUS REPLICON PARTICLE BHC; SEMLIKI FOREST VIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOTULISM; CLOSTRIDIUM BOTULINUM; CONTROLLED STUDY; DNA VECTOR; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; REPLICON; SEMLIKI FOREST ALPHAVIRUS;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; BOTULINUM TOXINS; BOTULINUM TOXINS, TYPE A; BOTULISM; CLOSTRIDIUM BOTULINUM; FEMALE; MICE; MICE, INBRED BALB C; REPLICON; SEMLIKI FOREST VIRUS; VACCINES, DNA;

EID: 70349764298     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.022     Document Type: Article

References (30)

1. Schiavo G., Matteoli M., and Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 80 (2000) 717-766
2. Turton K., Chaddock J.A., and Acharya K.R. Botulinum and tetanus neurotoxtins: structure, function and therapeutic utility. Trends Biochem Sci 27 11 (2002) 552-558
3. Byrne M.P., and Smith L.A. Development of vaccines for prevention of botulism. Biochimie 82 (2000) 955-966
4. Middlebrook J.L. Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology. Adv Drug Deliv Rev 57 (2005) 1415-1423
5. Smith L.A., and Rusnak J.M. Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol 27 (2007) 303-318
6. Clayton M.A., Clayton J.M., Brown D.R., and Middlebrook J.L. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun 63 (1995) 2728-2742
7. Byrne M.P., Smith T.J., Montgomery V.A., and Smith L.A. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun 66 (1998) 4817-4822
8. Smith L.A. Development of recombinant vaccines for botulinum toxin. Toxicon 36 (1998) 1539-1548
9. Holley J.L., Elmore M., Mauchline M., Minton N., and Titball R.W. Cloning expression and evaluation sub-unit vaccine against Clostridium type F toxin. Vaccine 19 (2001) 288-297
10. Tavallaie M., Chenal A., Gillet D., Pereira Y., Manich M., Gibert M., et al. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS Lett 572 (2004) 299-306
11. Baldwin M.R., Tepp W.H., Pier C.L., Bradshaw M., Ho M., Wilson B.A., et al. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect Immun 73 (2005) 6998-7005
12. Ravichandran E., Al-Saleem F.H., Ancharski D.M., Elias M.D., Singh A.K., Shamim M., et al. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 75 (2007) 3043-3054
13. Baldwin M.R., Tepp W.H., Przedpelski1 A., Pier C.L., Bradshaw M., Johnson E.A., et al. A subunit vaccine against the seven serotypes of botulism. Infect Immun 76 (2008) 1314-1318
14. Yu Y.Z., Li N., Zhu H.Q., Wang R.L., Du Y., Wang S., et al. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate. Vaccine 27 (2009) 2816-2822
15. Jennifer Clayton, John L., and Middlebrook. Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A. Vaccine 18 (2000) 1855-1862
16. Shyu R.H., Shaio M.F., Tang S.S., Shyu H.F., Lee C.F., Tsai M.H., et al. DNA vaccination using the fragment C of botulinum neurotoxin type A provided protective immunity in mice. J Biomed Sci 7 (2000) 51-57
17. Bennett A.M., Perkins S.D., and Holley J.L. DNA vaccination protects against botulinum neurotoxin type F. Vaccine 21 (2003) 3110-3117
18. Jathoul A.P., Holley J.L., and Garmory H.S. Efficacy DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters. Vaccine 22 (2004) 3942-3946
19. Lee J.S., Pushko P., Parker M.D., Dertzbaugh M.T., Smith L.A., and Smith J.F. Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect Immun 69 (2001) 5709-5715
20. Lee J.S., Groebner J.L., Hadjipanayis A.G., Negley D.L., Schmaljohn A.L., Welkos S.L., et al. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. Vaccine 24 (2006) 6886-6892
21. Yu Y.Z., Zhang S.M., Sun Z.W., Wang S., and Yu W.Y. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A. Vaccine 25 (2007) 8843-8850
22. Yu R., Wang S., Yu Y.Z., Yu W.Y., and Sun Z.W. High-level and soluble expressions of botulinum neurotoxin serotype B protective antigen Hc domain in Escherichia coli. Lett Biotechnol (in Chinese) 19 3 (2008) 365-367
23. Yu Y.Z., Sun Z.W., Liu Z.G., and Yu W.Y. High-level expression of foreign genes in vivo and in vitro by improved DNA-based replicon vector derived from Semliki Forest virus. Prog Biochem Biophys (in Chinese) 33 1 (2006) 87-94
24. Yu Y.Z., Sun Z.W., Wang S., and Yu W.Y. Expression of the Hc fargment of Clostridium botulinum neurotoxin serotype A in mammalian cells using recombinant Semliki Forest Virus Expression system. Chin J Biotech (in Chinese) 23 5 (2007) 812-817
25. DiCiommo D.P., and Bremner R. Rapid, high level protein production using DNA-based Semliki Forest virus vectors. J Bio Chem 273 29 (1998) 18060-18066
26. Ni B., Lin Z.H., Zhou L.Y., Wang L., Jia Z.C., Zhou W., et al. Induction of P815 tumor immunity by DNA-based recombinant Semliki Forest virus or replicon DNA expressing the P1A gene. Cancer Detection Prev 28 6 (2004) 418-425
27. Berglund P., Semerdou C., Fleeton M.N., Tubulekas I., and Liljestrom P. Enhancing immune responses using suicidal DNA vaccines. Nat Biotechnol 16 (1998) 562-565
28. Kirman J.R., Turon T., Su H., Li A., Kraus C., Polo J.M., et al. Enhanced immunogenicity to mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. Infect Immun 71 (2003) 575-579
29. Nordstrom E.K., Forsell M.N., Barnfieid C., Bonin E., Hanke T., Sundström M., et al. Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1. J Gen Virol 86 2 (2005) 349-354
30. Pushko P., Geisbert J., Parker M., Jahrling P., and Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol 75 23 (2001) 11677-11685